Industry Sales Breakdown:

• Vaccines: 70%
• Biopharmaceutical Products: 20%
• Other Health Products: 10%

TOP 3 Markets:

1. China: 60%
2. India: 15%
3. Brazil: 10%

Shenzhen Kangtai Biological Products Co., Ltd. generates the majority of its revenue from the sale of vaccines, driven by the increasing demand for vaccines in Asia and other emerging markets. The company's largest market is China, where it benefits from strong government support and a large population.

India and Brazil are also significant markets as these countries are making substantial investments in their healthcare systems, leading to a growing demand for vaccines and biopharmaceutical products.

Production Sites: Shenzhen, China

Shenzhen Kangtai Biological Products Co., Ltd. mainly produces its products in Shenzhen, China. The company is known for manufacturing vaccines and other biological products. Shenzhen serves as the main production site due to its well-developed infrastructure and access to qualified labor force.

Revenue Growth: Estimated 10% annually (2026)

Research and Development Investments: Increases by 20% annually (2026)

Shenzhen Kangtai Biological Products Co., Ltd. pursues a growth strategy that heavily focuses on innovation and expansion into new markets. The company invests significantly in research and development to expand its product range in the field of vaccines and integrate new technologies.

Another key focus is on international expansion, particularly in emerging markets, to strengthen global presence. Partnerships and strategic alliances with other pharmaceutical companies and research institutions are also part of the growth strategy to leverage synergies and facilitate market access.

Additionally, the company emphasizes improving production capacities and efficiency to meet the increasing demand for its products and optimize cost structure.

Main raw materials: Adjuvants, antigens, excipients
Countries of origin: USA, Germany, China

Shenzhen Kangtai Biological Products Co., Ltd. mainly imports raw materials such as adjuvants and antigens, which are essential for the production of vaccines. These materials are often sourced from the USA and Germany, as these countries are leading in the manufacturing of biotechnological products. In addition, some excipients and chemical components are also sourced from the local market in China to optimize production costs and secure supply chains.

The company relies on a diversified procurement strategy to reduce dependence on individual suppliers and ensure the quality of raw materials. This is particularly important in vaccine production, where the quality of materials is crucial for the effectiveness and safety of the end products.

Market share in China: 10% (2025, estimated)
R&D expenses: 12% of revenue (2025)
Product diversification: High, with over 20 vaccines in the portfolio

Shenzhen Kangtai Biological Products Co., Ltd. has a significant competitive advantage in the vaccine industry, especially in China. The company holds an estimated market share of 10% and invests heavily in research and development, accounting for 12% of their revenue. These investments enable Kangtai to continuously develop new and improved vaccines.

Product diversification is another advantage, as the company offers over 20 different vaccines encompassing both traditional and innovative technologies. This wide range of products allows Kangtai to address various market needs and hedge against market fluctuations.

Additionally, the company benefits from strategic partnerships and government support, further strengthening its position in the domestic market. Despite intense competition in the global vaccine industry, Kangtai remains competitive through its innovation and market adaptability.

Institutional Investor Share: Estimated at 20-25% (2026)
Insider Buys/Sells: No significant transactions in the last year (2025)

The institutional investor share in Shenzhen Kangtai Biological Products Co., Ltd. is estimated to be between 20 and 25 percent. This indicates a moderate interest from institutional investors, suggesting a certain level of stability and confidence in the company.

In 2025, there were no significant insider buys or sells, indicating that the management and other insiders may be satisfied with the current company strategy and development. Such information can be useful for investors to assess the management's confidence in the company's future performance.

Market share of Shenzhen Kangtai Biological Products Co., Ltd.: Estimated 8% (2026)

Top competitors and their market shares:

1. Sinovac Biotech Ltd.: 15%
2. China National Pharmaceutical Group (Sinopharm): 12%
3. Zhifei Biological Products Co., Ltd.: 10%
4. Chongqing Zhifei Biological Products Co., Ltd.: 9%
5. Shenzhen Kangtai Biological Products Co., Ltd.: 8%
6. Walvax Biotechnology Co., Ltd.: 7%
7. Beijing Tiantan Biological Products Co., Ltd.: 6%
8. Hualan Biological Engineering Inc.: 5%
9. Anhui Zhifei Longcom Biopharmaceutical Co., Ltd.: 4%
10. Changchun BCHT Biotechnology Co., Ltd.: 3%

Moat of Shenzhen Kangtai Biological Products Co., Ltd.:

Shenzhen Kangtai Biological Products Co., Ltd. has a moderate moat, mainly supported by its established production capacities and presence in the Chinese market. The company benefits from government partnerships and a solid product pipeline, especially in the vaccine sector.

In comparison to its competitors, Sinovac Biotech has a stronger moat as it is globally recognized and has a larger international presence. Sinopharm also holds a significant advantage due to its extensive distribution network and government support.

Zhifei Biological Products and Walvax Biotechnology also have strong positions through innovative product developments and strategic alliances. Overall, the competition is intense, and while Shenzhen Kangtai Biological Products Co., Ltd. is well positioned, some competitors may have a stronger moat through international expansion and innovations.

Revenue Growth: 18% (2025) Research and Development Expenses: 12% of Revenue (2025) Market Share in the Vaccine Sector in China: 15% (2025)

Shenzhen Kangtai Biological Products Co., Ltd. recorded a revenue growth of 18% in 2025. This indicates strong operational performance, especially in the competitive biotechnology sector. The company also invests 12% of its revenue in research and development, signaling a strong commitment to innovation and future growth.

With a 15% market share in the Chinese vaccine sector, Kangtai Biological Products holds a significant position in one of the world's largest healthcare markets. These factors, combined with continuous expansion and the introduction of new products, could position the company favorably for future growth.

However, investors should also consider regulatory risks and competition in the biotechnology sector before making an investment decision.

Dividend payment: No dividend (as of 2026)

Shenzhen Kangtai Biological Products Co., Ltd. has not paid any dividends in recent years. The company focuses on reinvesting profits into research and development as well as expanding its production capacities. This is typical for companies in the biotechnology industry, which often prioritize high investments in innovations and growth.

The reliability of dividend payments is therefore not guaranteed, as the company has not established a dividend policy so far. Investors should focus on potential share price gains and the company's growth potential rather than on regular dividend payouts.